Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.55 |
| ▸ | CASR | P41180 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6003044 | 0.86 | LTA4H (0.56) | LTA4HCASRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6003045 | 0.85 | LTA4H (0.55) | LTA4HCASRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11574994 | 0.83 | LTA4H (0.50) | LTA4HCASRALDH1A1MAPTKMT2A | |
| SCHEMBL6004422 | 0.81 | CASR (0.67) | LTA4HCASRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9816133 | 0.81 | LTA4H (0.51) | LTA4HCASRALDH1A1KMT2A | |
| SCHEMBL6004389 | 0.81 | CASR (0.55) | LTA4HCASR | |
| SCHEMBL14791465 | 0.81 | CASR (0.55) | LTA4HCASR | |
| SCHEMBL12329175 | 0.81 | CASR (0.73) | CASR | |
| SCHEMBL11615880 | 0.79 | LTA4H (0.68) | LTA4HCASRKMT2A | |
| SCHEMBL6004419 | 0.78 | CASR (0.66) | LTA4HCASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281394-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281394-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012054530-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281394-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | LTA4H 686/4885CASR 150/4885ALDH1A1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.